DE60232895D1 - Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort - Google Patents
Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwortInfo
- Publication number
- DE60232895D1 DE60232895D1 DE60232895T DE60232895T DE60232895D1 DE 60232895 D1 DE60232895 D1 DE 60232895D1 DE 60232895 T DE60232895 T DE 60232895T DE 60232895 T DE60232895 T DE 60232895T DE 60232895 D1 DE60232895 D1 DE 60232895D1
- Authority
- DE
- Germany
- Prior art keywords
- agonistic
- antibodies
- improve
- immune response
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000028993 immune response Effects 0.000 title abstract 2
- 230000001270 agonistic effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32800401P | 2001-10-09 | 2001-10-09 | |
PCT/US2002/032364 WO2003049755A1 (en) | 2001-10-09 | 2002-10-09 | Enhancement of immune responses by 4-1bb-binding agents |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60232895D1 true DE60232895D1 (de) | 2009-08-20 |
Family
ID=23279079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60232895T Expired - Lifetime DE60232895D1 (de) | 2001-10-09 | 2002-10-09 | Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort |
Country Status (7)
Country | Link |
---|---|
US (3) | US7651686B2 (de) |
EP (1) | EP1434596B1 (de) |
AT (1) | ATE435655T1 (de) |
AU (1) | AU2002364935A1 (de) |
DE (1) | DE60232895D1 (de) |
ES (1) | ES2328025T3 (de) |
WO (1) | WO2003049755A1 (de) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1234031B2 (de) | 1999-11-30 | 2021-11-24 | Mayo Foundation For Medical Education And Research | B7-h1, ein neuartiges immunregulierendes molekül |
WO2003049755A1 (en) * | 2001-10-09 | 2003-06-19 | Mayo Foundation For Medical Education And Research | Enhancement of immune responses by 4-1bb-binding agents |
US20040109847A1 (en) * | 2002-07-15 | 2004-06-10 | Lieping Chen | Treatment and prophylaxis with 4-1BB-binding agents |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
US20070253961A1 (en) * | 2004-06-09 | 2007-11-01 | Ulsan Industrial Education Foundation | Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis |
PL1810026T3 (pl) | 2004-10-06 | 2018-08-31 | Mayo Foundation For Medical Education And Research | B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego |
US20060182744A1 (en) * | 2005-02-15 | 2006-08-17 | Strome Scott E | Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof |
EP1851244A4 (de) * | 2005-02-15 | 2009-04-15 | Gtc Biotherapeutics Inc | Anti-cd137-antikörper als mittel für die behandlung von krebs, und glykosylierungsvarianten davon |
US20080019905A9 (en) * | 2005-02-18 | 2008-01-24 | Strome Scott E | Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
WO2006088464A2 (en) * | 2005-02-15 | 2006-08-24 | Gtc Biotherapeutics, Inc. | A method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
ES2642787T3 (es) * | 2005-10-21 | 2017-11-20 | Lfb Usa, Inc. | Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso |
WO2007082144A2 (en) * | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | B7-h1 and survivin in cancer |
US20090215084A1 (en) * | 2006-01-05 | 2009-08-27 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
MY160857A (en) * | 2006-02-03 | 2017-03-31 | Malaysian Palm Oil Board | A cancer vaccine |
WO2007124361A2 (en) * | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
WO2009042773A1 (en) * | 2007-09-25 | 2009-04-02 | University Of Miami | Adoptively transferred tumor-specific t cells stimulated ex vivo using herpes simplex virus amplicons |
US20110020325A1 (en) * | 2008-02-29 | 2011-01-27 | Kwon Eugene D | Methods for reducing granulomatous inflammation |
US20110229460A1 (en) * | 2008-05-01 | 2011-09-22 | Gtc Biotherapeutics, Inc. | anti-cd137 antibody as an agent in the treatment of inflammatory conditions |
ES2377785B2 (es) | 2010-09-08 | 2012-09-26 | Universidad Miguel Hernández De Elche | Composición farmacéutica para el tratamiento del ojo seco. |
SG10201506906VA (en) | 2010-09-09 | 2015-10-29 | Pfizer | 4-1bb binding molecules |
CA2823005C (en) | 2010-12-30 | 2019-07-09 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Glycols as pathogen inactivating agents |
CA2775206C (en) | 2011-04-27 | 2019-02-26 | Perspecsys Inc. | System and method of handling requests in a multi-homed reverse proxy |
WO2012145825A1 (en) * | 2011-04-27 | 2012-11-01 | Perspecsys Inc. | System and method for data obfuscation in interception of communication with a cloud |
JP5643716B2 (ja) * | 2011-05-31 | 2014-12-17 | 楽天株式会社 | 情報処理システム、情報処理方法、情報処理装置、情報処理端末、プログラム及び記録媒体 |
WO2014125374A2 (en) | 2013-02-13 | 2014-08-21 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
AR094778A1 (es) | 2013-02-13 | 2015-08-26 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteínas con glicosilación modificada y métodos para producirlas |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
EP3404116B1 (de) * | 2013-03-15 | 2022-10-19 | The University of Chicago | Verfahren und zusammensetzungen in zusammenhang mit t-zell aktivität |
EP3016729B1 (de) | 2013-07-05 | 2020-03-25 | Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme | Affinitätschromatografiematrix |
ES2714708T3 (es) | 2013-10-01 | 2019-05-29 | Mayo Found Medical Education & Res | Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim |
KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
US10302653B2 (en) | 2014-05-22 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti B7-H1 antibodies |
EP3171896A4 (de) | 2014-07-23 | 2018-03-21 | Mayo Foundation for Medical Education and Research | Abzielung auf dna-pkcs und b7-h1 zur behandlung von krebs |
DK3253876T3 (da) * | 2015-02-06 | 2021-01-25 | Heat Biologics Inc | Vektor, der co-ekspresserer vaccine og costimulerende molekyler |
WO2016134358A1 (en) | 2015-02-22 | 2016-08-25 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd137 |
CA2980622A1 (en) * | 2015-04-02 | 2016-10-06 | Cancure Limited | Agents and compositions for eliciting an immune response |
US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
WO2018085854A1 (en) * | 2016-11-07 | 2018-05-11 | Advaxis, Inc. | Combination of listeria-based vaccine with anti-ctla-4 or anti-cd137 antibodies |
US11512134B2 (en) | 2017-08-01 | 2022-11-29 | Eli Lilly And Company | Anti-CD137 antibodies |
BR112019007714B1 (pt) | 2017-01-06 | 2022-01-18 | Eutilex Co., Ltd | Anticorpos anti-4-1bb, uso do mesmo, composição farmacêutica, métodos para determinar uma dose, para aumentar a secreção de ifn-gama por uma célula in vitro e para proliferação ex vivo ou isolamento de células t ativadas e uso das mesmas |
AU2018224094A1 (en) | 2017-02-24 | 2019-09-19 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
CA3059366A1 (en) | 2017-04-13 | 2018-10-18 | Agenus Inc. | Anti-cd137 antibodies and methods of use thereof |
CN116731180A (zh) * | 2017-06-25 | 2023-09-12 | 西雅图免疫公司 | 抗ror1抗体及其制备和使用方法 |
KR20200035966A (ko) | 2017-07-11 | 2020-04-06 | 콤파스 테라퓨틱스 엘엘씨 | 인간 cd137에 결합하는 작동자 항체 및 이의 용도 |
CA3146758A1 (en) * | 2017-08-01 | 2019-02-07 | Eli Lilly And Company | Anti-cd137 antibodies |
WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
WO2019109238A1 (en) * | 2017-12-05 | 2019-06-13 | Lyvgen Biopharma Co., Ltd. | Anti-cd137 antibodies and uses thereof |
RU2020127196A (ru) | 2018-01-22 | 2022-02-24 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Антитело против 4-1bb, его антигенсвязывающий фрагмент и его медицинское применение |
EP3966252A4 (de) | 2019-05-10 | 2023-01-25 | Lyvgen Biopharma Holdings Limited | Humanisierte anti-cd137-antikörper und verwendungen davon |
WO2021137230A1 (en) | 2019-12-31 | 2021-07-08 | Kahr Medical Ltd. | Methods of culturing t cells and uses of same |
WO2021137231A1 (en) | 2019-12-31 | 2021-07-08 | Kahr Medical Ltd. | Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4257774A (en) | 1979-07-16 | 1981-03-24 | Meloy Laboratories, Inc. | Intercalation inhibition assay for compounds that interact with DNA or RNA |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US6303121B1 (en) * | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
US7211259B1 (en) | 1993-05-07 | 2007-05-01 | Immunex Corporation | 4-1BB polypeptides and DNA encoding 4-1BB polypeptides |
US5674704A (en) | 1993-05-07 | 1997-10-07 | Immunex Corporation | Cytokine designated 4-IBB ligand |
KR100244960B1 (ko) | 1993-09-16 | 2000-02-15 | 왈터 엘 쿤, 주니어 | 인간 수용체 h4-1bb |
WO1996029348A1 (en) | 1995-03-23 | 1996-09-26 | Indiana University Foundation | Monoclonal antibody against human receptor protein 4-1bb and methods of its use for treatment of diseases |
WO1996032495A1 (en) | 1995-04-08 | 1996-10-17 | Lg Chemicals Ltd. | Monoclonal antibody specific for human 4-1bb and cell line producing same |
US5874240A (en) | 1996-03-15 | 1999-02-23 | Human Genome Sciences, Inc. | Human 4-1BB receptor splicing variant |
ATE230801T1 (de) | 1996-10-03 | 2003-01-15 | Canon Kk | Verfahren zur detektion von zielnukleinsäure, verfahren zu ihrer quantifizierung und pyrylium- verbindungen zur chemilumineszenz-analyse |
CA2268340A1 (en) * | 1996-10-11 | 1998-04-23 | Bristol-Myers Squibb Company | Methods and compositions for immunomodulation |
AU6534898A (en) | 1997-02-14 | 1998-09-08 | E.I. Du Pont De Nemours And Company | Detection of double-stranded dna in a homogeneous solution |
KR20000034847A (ko) | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
US6734172B2 (en) * | 1998-11-18 | 2004-05-11 | Pacific Northwest Research Institute | Surface receptor antigen vaccines |
WO2000041508A2 (en) * | 1999-01-15 | 2000-07-20 | Mount Sinai School Of Medicine Of The City University Of New York | Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines |
US20020177551A1 (en) * | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
JP2003523768A (ja) | 2000-02-25 | 2003-08-12 | イミュネックス・コーポレーション | インテグリンアンタゴニスト |
WO2002004009A2 (en) * | 2000-07-12 | 2002-01-17 | Immunex Corporation | Method for treating cancer using an interleukin- 4 antagonist |
AU2001288863A1 (en) * | 2000-09-15 | 2002-03-26 | Ortho-Mcneil Pharmaceutical, Inc. | Compositions and methods for inducing specific cytolytic t cell responses |
US20040247563A1 (en) * | 2000-11-02 | 2004-12-09 | Lynch David H. | Method of enhancing lymphocyte-mediated immune responses |
AU2002246756A1 (en) * | 2000-12-26 | 2002-08-06 | Bristol-Myers Squibb Company | Use of combretastatin a4 and its prodrugs as an immune enhancing therapy |
AU2002322211A1 (en) | 2001-07-12 | 2003-01-29 | Canvac | Methods and compisitions for activation human t cells in vitro |
WO2003049755A1 (en) | 2001-10-09 | 2003-06-19 | Mayo Foundation For Medical Education And Research | Enhancement of immune responses by 4-1bb-binding agents |
US20030223989A1 (en) | 2002-04-18 | 2003-12-04 | Pluenneke John D. | CD137 agonists to treat patients with IgE-mediated conditions |
-
2002
- 2002-10-09 WO PCT/US2002/032364 patent/WO2003049755A1/en not_active Application Discontinuation
- 2002-10-09 EP EP02802551A patent/EP1434596B1/de not_active Expired - Lifetime
- 2002-10-09 DE DE60232895T patent/DE60232895D1/de not_active Expired - Lifetime
- 2002-10-09 AT AT02802551T patent/ATE435655T1/de not_active IP Right Cessation
- 2002-10-09 US US10/492,056 patent/US7651686B2/en active Active
- 2002-10-09 AU AU2002364935A patent/AU2002364935A1/en not_active Abandoned
- 2002-10-09 ES ES02802551T patent/ES2328025T3/es not_active Expired - Lifetime
-
2009
- 2009-11-06 US US12/614,150 patent/US8163550B2/en not_active Expired - Lifetime
-
2012
- 2012-03-21 US US13/426,151 patent/US8772026B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US8163550B2 (en) | 2012-04-24 |
ES2328025T3 (es) | 2009-11-06 |
AU2002364935A1 (en) | 2003-06-23 |
US7651686B2 (en) | 2010-01-26 |
US20120225043A1 (en) | 2012-09-06 |
EP1434596B1 (de) | 2009-07-08 |
EP1434596A1 (de) | 2004-07-07 |
WO2003049755A1 (en) | 2003-06-19 |
US20100266611A1 (en) | 2010-10-21 |
US8772026B2 (en) | 2014-07-08 |
ATE435655T1 (de) | 2009-07-15 |
EP1434596A4 (de) | 2004-12-15 |
US20050013811A1 (en) | 2005-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60232895D1 (de) | Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort | |
GT200800132A (es) | Anticuerpos anti-il-23 humanos, composiciones, metodos y usos | |
ATE255420T1 (de) | Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung | |
ATE500323T1 (de) | Subtilisin-variante | |
DK1525320T3 (da) | Fremgangsmåde til ekspression af rekombinant protein i CHO-celler | |
ATE172743T1 (de) | Nachweis von kollagenabbau -i(in vivo) | |
DK1140173T4 (da) | Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf | |
HK1074670A1 (en) | Sets of digital antibodies directed against short epitopes, and methods using same | |
TR200003181T2 (tr) | Gelişmiş çoğaltılabilirliğe sahip FAP alfa'ya özgü antikor | |
NO20083160L (no) | Methods for obtaining immortalized anitbody secreting cells | |
DK1650307T3 (da) | Fremgangsmåde til fremstilling af rekombinante proteiner ved anvendelse af apoptoseinhibitorer | |
BR0314814A (pt) | Variantes otimizadas de fc e métodos para sua geração | |
CY1111520T1 (el) | Μεθοδοι σχηματισμου εξανθρωπισμενων αντισωματων μεσω τυχαιας μεταλλαξογεννησης | |
DK0914155T3 (da) | Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen | |
ATE286907T1 (de) | Cytokinin-designiertes lerk-5 | |
CR8231A (es) | Anticuerpos rg1 y uso de los mismos | |
AR035352A1 (es) | Anticuerpos anti-lt-beta-r humanizados | |
DK1492869T3 (da) | Transplantataccept-inducerende celler af monocytisk oprindelse, deres fremstilling og anvendelse | |
DE60232234D1 (de) | Verfahren zur kultivierung von circovirus | |
DE69841015D1 (de) | Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2 | |
DK1321477T3 (da) | Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner | |
TR200102034T2 (tr) | Anti kanser aşılaması için antikorların kullanılması | |
EA200200974A1 (ru) | Моноклональные антитела к рецептору лпнп человека, их получение и применение | |
ATE466874T1 (de) | Mit scytovirin der domäne 1 verwandte polypeptide | |
DE69115917T2 (de) | Humane gammainterferonantagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |